Arsenic trioxide

Drug Profile

Arsenic trioxide

Alternative Names: NSC-706363; Trisenox

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator CTI BioPharma
  • Developer Leukemia SPORE; Northwestern University; Temple University; Teva Pharmaceutical Industries; University of Texas M. D. Anderson Cancer Center
  • Class Anti-inflammatories; Antineoplastics; Arsenicals; Ischaemic heart disorder therapies; Oxides; Small molecules
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Myelodysplastic syndromes; Liver cancer; Chronic myeloid leukaemia; Acute myeloid leukaemia; Acute promyelocytic leukaemia; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute promyelocytic leukaemia
  • Phase II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase I/II Glioma
  • Discontinued Multiple myeloma

Most Recent Events

  • 22 Nov 2016 Launched for Acute promyelocytic leukaemia (Combination therapy, Newly diagnosed) in Slovakia, Luxembourg, Lithuania, Latvia, Czech Republic, Poland, Belgium, Greece, Italy, Portugal, Spain, Finland, Denmark, Sweden, Austria, France, Ireland, Netherlands, United Kingdom and Germany (IV)
  • 21 Nov 2016 Registered for Acute promyelocytic leukaemia (Combination therapy, Newly diagnosed) in European Union (IV)
  • 17 Oct 2016 Preregistration for Acute promyelocytic leukaemia (Newly diagnosed, Combination therapy) in European Union (IV) before October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top